CAMP earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -1.37. Updated 2026-07-23.
CAMP4 Therapeutics (CAMP) Research Hub
CAMP4 Therapeutics (CAMP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 4.25 USD (-1.85%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.37, market cap 0.07B. This hub links to the full technical, earnings and options research available for CAMP.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.25 USD (-1.85%) |
| 52-week range | 2.9 USD – 6 USD |
| Trend regime | Range |
| 14-day RSI | 50.2 (Neutral) |
| Trailing P/E | -1.37 |
| Market cap | 0.07B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for CAMP
Covered Call on CAMP: how it works, illustrative setup around the real 4.25 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CAMP: how it works, illustrative setup around the real 4.25 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CAMP: how it works, illustrative setup around the real 4.25 USD price, max profit/loss, breakeven and when to use it. Educational.
CAMP technical analysis: range, last 4.25 USD, RSI 50.2, 52w range 2.9 USD–6 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CAMP in?
CAMP4 Therapeutics (CAMP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CAMP in an uptrend or downtrend?
As of 2026-09-11, CAMP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CAMP's trailing P/E ratio?
CAMP's trailing P/E is -1.37, with a market cap of 0.07B. See the earnings research page for full valuation detail.
When does CAMP next report earnings?
CAMP is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.24 USD.